ANN ARBOR, Mich., – November 4, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that its operations team at its Vietnamese subsidiary, Prodigy Textiles, has completed rearing the Company’s first batch of production silkworms.  The Company’s specialized spider silk silkworms were hatched over a 7 day period starting on October 8^th, while Jon Rice, the Company’s COO, was in Vietnam.  The silkworms began spinning cocoons on October 27^th and finished on November 2^nd. 

The Company is already in the process of removing the finished cocoons from the mounting frames, which will be complete by November 6^th.  Upon completion, the cocoons will be prepared for the silk moths to emerge.  As reported, late last month, the entire population of emerging silk moths will be dedicated to breeding stock, in order to rapidly expand the Company silk production capacity at Prodigy Textiles.

The second round of production is slated to begin later this month and the resulting silk cocoons will be reeled and spun into finished silk thread.  This thread will be the first recombinant spider silk thread available from Prodigy Textiles and is scheduled to be delivered to a collaborative partner the Company has been working with to develop new materials and applications. 

With operations now fully underway, the Company expects to maintain a continuous production output at Prodigy Textiles and will plan to bring additional materials to market to address the backlog of inquiries in the coming months. 

“The Prodigy Textiles production ramp up continues to demonstrate the efficacy of our manufacturing strategy. The success of this first wave of operations will serve as the blueprint for the successive expansion.  Our direct, drop-in strategy is already proving its effectiveness to scale Dragonsilk 2.0.   We believe this demonstration of rapid expansion will clear the path to fast-track our operations growth and quickly reach our targeted capacity,” Rice said.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – Oct 28, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that operations at its Vietnamese production facility, which just formally kicked off earlier this month, are on track to set new production capacity records for the Company.

As expected, the first batch of production silkworms, announced earlier this month, are thriving on their diet of fresh mulberry leaves and the warm, humid climate at the facility in Vietnam. 

The Company expects that this first round of production will be complete within two to three weeks.  The entire population of emerging silk moths, from this first production cycle, will be dedicated to breedstock population expansion, resulting in a more than a 100x increase in silkworm egg production and preparing for what the Company believes will be its largest production batch, scheduled for November. 

The November production batch, in Vietnam, is expected to expand the Company’s capacity to produce its specialized recombinant spider silk to a level that collectively exceeds the entirety of its U.S based production, over the last ten years. 

This critical milestone, in the Company’s commercialization of eco-friendly and cost effective recombinant spider silk, has been the key focus of Company management’s initiative to create high performance and environmentally sustainable alternatives to synthetic textiles. The completion of this first wave of production is validating the Company’s business model and its transgenic spider silk silkworms. The Company expects that its factory will have capacity to produce more than 8 metric tons of its specialized silk in 2020, with a total capacity of roughly 40 metric tons per year, once fully utilized.

“There has been considerable interest in Kraig Labs’ high performance fibers, from multiple internationally recognized brands, so bringing our specialized silkworms online should allow us to deliver our first large batch of fabric and begin to fulfill the fiber request backlog,” said COO Jon Rice.  “Having now successfully delivered the silkworms to the factory, watched our team hard at work rearing this first batch, and preparing the factory for the expanding workload, and walked the rows of silk production rack, tray, and mounting boxes, I believe that we are on track to meet our production targets for 2020.”  

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – Oct 8, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, is very happy to announce today that the Company has officially initiated commercial production scale up of its recombinant spider silk production at its Vietnamese subsidiary, Prodigy Textiles.  During a trip this week Jon Rice, the Company’s chief operating officer, successfully delivered the Company’s specialized silkworm eggs to the production team, at Prodigy Textiles’ recently renovated factory.  This moment marks a pivotal milestone in the commercialization and production of eco-friendly and cost effective recombinant spider silk. 

“The significance of today’s announcement can’t be overstated.  By clearing this critical production hurdle, we are now aggressively ramping up to produce and fill demand for our recombinant spider silk materials,” said Rice. “Having demonstrated our materials’ performance capabilities and secured necessary approvals, we are now focused on the exciting next phase of our business model; delivering our high performance silk yarns to the market and formalizing strategic partnerships.  Our dream of a sustainable and cost effective method to produce recombinant spider silk is now in operation.”

With capacity scale up now officially underway in Vietnam, the Company is focused on the production of its recombinant spider silk threads and yarns for delivery to collaborative partners and target market segments.

The Company has been working with senior officials in Vietnam for several years to secure the necessary permits and approvals needed to bring its revolutionary spider silk technology to production.  The delivery of these progenitor silkworms into the Company’s Vietnamese facility marks the success of that process and the beginning of a new era in performance textiles. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – October 2, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that Jon Rice, the Company’s chief operating officer, will travel to Vietnam, this week, to work with the Company’s subsidiary, Prodigy Textiles, on the transition of silk production operations into its recently renovated facility in Quang Nam province.  During this trip, Rice expects to review the completed facility improvements, coordinate operations with Prodigy Textiles senior staff and production workers, finalize production and transportation logistics, discuss production throughput rates and targets, as well as review the security and quality control systems being implemented. 

 “Our staff, in the U.S. and Vietnam, has put an incredible amount of effort into establishing and preparing Prodigy Textiles to disrupt the performance textile markets.  Our team has pushed through incredible challenges to bring this factory online.  We are now ready to put it to work, bringing our recombinant spider silk technology to market.  I expect to be able to share more information about my trip and details about our operations with our shareholders early next week,” said Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – Sept 25, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that, with the appointment of Mr. Greg Scheessele, as the third and final independent Board member, it has completed the selection of independent members for its Board of Directors.

Mr. Scheessele currently serves as the CEO of Gerette, LLC and has held several top executive roles in global manufacturing firms including: Executive Vice President, TMD Americas at TMD Friction Holdings GmbH; Group Vice President, Global Operations at Pall Corporation and Gelman Sciences; and Manufacturing Manager at General Motors Powertrain Division.  Mr. Scheessele has served on various corporate and non-profit boards over the past twelve years.

Over the last two weeks the Company announced the selections of three new independent directors scheduled to join the Company’s board during the fourth quarter, including Mr. Anurag Gupta, Ms. Julie Bishop, and Mr. Greg Scheessele.  The Company anticipates selecting one additional inside director to round out its board.

“We are pleased to welcome Greg to the Kraig Lab’s board in the role of an independent director,” said chairman and CEO, Kim Thompson.  “Greg’s background, experience, and leadership focused in businesses with global operations in manufacturing, industrial and life sciences sectors will be a tremendous asset to our corporate strategy as we continue on our growth trajectory.  With this announcement, the Company has reached a new and important milestone in its corporate governance, advancing our business model.”

The addition of Mr. Scheessele to the board will expand the overall skillset, perspective and experience necessary to support and drive growth for all of the Company’s stakeholders.  Mr. Scheessele has a strong history of leading successful business operations on a global scale.

Mr. Scheessele’s term will begin during the fourth quarter and he will serve on the audit and compensation committees for the duration of his time as a director.

Once these three new independent directors are formally seated, during the fourth quarter, the Company will be governed by a majority of independent directors, which is a key requirement for listing on a national exchange.

“I am very excited to join the Kraig Biocraft Laboratories board,” said Mr. Scheessele.  “I look forward to supporting Kim Thompson and his team with their exciting work focusing on the development and commercialization of spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – Sept 20, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that has selected Ms. Julie Bishop for its expanded Board of Directors.  Ms. Bishop currently serves as the Senior Director of Global Accounting at Verizon Media and has held senior accounting positions at Yahoo and HD Waterworks.  Prior to this, Ms. Bishop spent seven years serving as an auditor for publicly traded companies while working at Ernst & Young.

“We are pleased to welcome Julie, who will be joining the Kraig Lab’s board, as a new independent director,” said, chairman and CEO, Kim Thompson.  “Julie’s background, experience, and leadership, in corporate finance, accounting, merger and acquisitions, and audit, will be a tremendous asset to our corporate governance as we continue on our growth trajectory.”

The addition of Ms. Bishop to the board will expand the overall skillset, perspective and experience necessary to support and drive growth for all of the Company’s stakeholders.  Ms. Bishop is a licensed C.P.A with extensive experience in finance and auditing for publicly traded companies.

Ms. Bishop’s term will begin during the fourth quarter and she will serve on the audit and compensation committees for the duration of her time as a director.

“I am thrilled to have been selected for appointment to the Kraig Labs board of Directors,” said Ms. Bishop.  “I look forward to helping oversee the company as it moves to commercialize its next generation protective textile products and realize the potential of its cutting edge technology.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Labs adds first biological engineer to R&D team bringing extensive spider silk experience

ANN ARBOR, Mich., – August 20, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has expanded its team with the addition of its first biological engineer to the R&D department.  This new hire brings extensive experience working with spider silks. Working directly with Kraig’s Chief Scientist, she is already developing new and stronger transgenics and providing valuable input shaping the direction the Company’s research is headed.

Her input in protein design combined with the Company’s breakthroughs in accelerating the rate of transgenic achievements should result in rapid prototyping of new and exciting silk materials. As a biological engineer, with a background in spider silk, she fits in very well with the culture of the Company and has already brought innovative ideas to streamline Kraig Labs’ R&D processes. Additionally, she possesses experience with sericulture and has implemented new procedures in the Company’s facility to ensure the continued production of the best quality fibers.

“I am very excited to add an engineer to our molecular biology team.  She is extremely impressive with her depth of knowledge and experience with sericulture, recombinant proteins, spider silks, and material properties. She has already made several important contributions to our R&D and I am looking forward to future breakthroughs,” said Chief Scientist, Dr. Trevor Kane.  “We were very fortunate to have found a bio-engineer with a background in spider silk and extensive research experience.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – August 8, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has completed construction of its new biotech research laboratory in Vietnam.  The new laboratory suite is located within the Company’s recombinant spider silk production facility in Quang Nam, Vietnam and consists of eleven separate labs.  These new labs are a key piece of the Company’s spider silk commercialization program and were part of the, now complete, renovation efforts at the Prodigy Textiles factory, the Company’s wholly owned subsidiary and production arm. 

This new laboratory suite was built to support production ramp up and will serve as a testing and quality control facility for the commercialization of the Company’s recombinant spider silk technologies.  To ensure compliance with regulations, related to genetically modified technologies, this laboratory was built to the design and specification of the Vietnamese Ministry of Science and Technology (MoST).  Moving into the future, the Company anticipates utilizing these new laboratories for the development of future innovations in spider silk fibers and products to compliment the Company’s existing technologies, which are now moving to commercialization.

“With these new laboratories and the completion of the Prodigy Textiles factory renovations, we are now ready to start the transition and expansion of our recombinant spider silk production into the new factory,” said COO Jon Rice.  “We purposefully designed our laboratories to mirror those of the MoST, where the initial evaluation and approval of our specialized silkworms were finalized, in order to accelerate our commercial ramp up.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Labs shareholders approve all ballot proposals

ANN ARBOR, Mich., – July 29, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that the Company’s shareholders have voted to approve uplisting to a national securities exchange, during its annual shareholder meeting (“meeting”) held on July 24.  Additionally, shareholders overwhelmingly approved all proposed ballot measures. 

The meeting attendance greatly exceeded Company management’s expectations, including shareholders from outside of the US in the audience.  Originally planned for forty five minutes, the meeting lasted for over three and a half hours, with Company management holding open question and answer sessions during both the formal and informal portions of the meeting. 

Kim Thompson, the founder and CEO of Kraig Labs, provided a presentation to shareholders on the significance of the Company strategy to uplist to a national exchange and the underlying efforts the Company has made to prepare for this transition. 

Jon Rice, the Company’s COO, shared an overview of the Company’s multiphase production model, progress in the buildout of its overseas factory, and the Company’s go to market strategies leveraging collaborations with leading brands in select market channels. 

Several member of the Kraig Labs staff were in attendance at the meeting, including Dr Trevor Kane, the Company’s newly appointed Chief Scientist.  Samples of the Company’s recombinant spider silk thread and silkworms, at each stage of the lifecycle, were on display for shareholders to see and touch. 

“I believe that today’s shareholder vote and approval of all of the ballot measures puts Kraig Labs on a solid footing for our future growth,” said Thompson.  “I would like to personally thank all of our shareholders for their support of the proposals.  With their overwhelming support and encouragement we are emboldened to carry forward with our plans to disrupt the textile markets with our eco-friendly and affordable recombinant spider silk.” 

Cautionary Statement:  While management and shareholders have approved an uplist, there can be no guarantee that these plans will come to fruition.  There are a number of obstacles that the Company will have to successfully navigate before an uplist can be implemented. 

“The shareholder meeting was an absolute success.  It was a pleasure to meet with so many of our shareholders and share our mutual excitement for the future of Kraig Labs,” said COO Jon Rice.

Details of the voting results can be found on the Company’s website, please go to www.KraigLabs.com/sec-filings/

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

July 14th Letter to Shareholders in preparation for the Annual meeting

Dear Kraig Labs Family,

Last week we shared the news of the Company’s upcoming annual shareholder meeting to be held on July 24th.  We have now completed the mailing of those notices, they should be arriving shortly.  We have also made the notice and proxy voting card available on the Company website at www.kraiglabs.com/shareholder-meeting.  If you do not receive a direct mailed notice it may be because your stock is held by a brokerage firm that received the notice.  Please don’t worry, as you can still print and mail in the proxy card from the Company website to have your vote counted.  We encourage all of our shareholders, who owned shares as of the record date, June 12, 2019, to complete and return their proxy voting card, regardless of whether you plan to attend the meeting in person or not.

As we look forward to the upcoming meeting and continue to work towards positioning the Company for the next stage of growth, we thought it appropriate to reflect on recently achieved major accomplishments and to share our immediate goals for our growth and expansion of our operations.

In the last 24 months the Company has transformed itself from a small R&D focused group to a company that management believes is on the verge of becoming the global supplier of spider silk materials.  In this time we have:

• Established Prodigy Textiles Ltd., our wholly owned Vietnamese subsidiary, which has been granted authorization and business licenses to open recombinant spider silk production operations.
• Signed a development agreement with a market leader in high performance textiles, to create the next generation of non-woven protective fabrics using spider silk.
• Secured a factory in Vietnam, to produce our recombinant spider silk, and signed agreements with suppliers and service providers to support growth.
• Produced the first sample of woven Dragon Silk fabric.
• Successfully completed a first of its kind, international shipment of transgenic silkworms.
• Established and staffed the Company’s first standalone R&D headquarters.
• Created new transgenics with the potential to surpass our existing technologies.
• Implemented new processes rapidly accelerating the pace of new transgenic development.
• Expanded our intellectual property position with additional provisional patent filings.
• Implemented new production quality control systems in preparation for rapid expansion.

With all of these achievements secured, the Company now looks to the future and how best to serve our shareholders, and meet the market demand for our remarkable products.  The expansion of our production operations will require capital, but we must be judicious in how we raise these funds. 

On the financial front, the Company has operated for over 10 years in the “Over The Counter” market (OTC) and managed to prosper, despite the OTC’s significant limitations.  Operating as an OTC company has limited our ability to raise capital from institutional investors, most of whom are prohibited by law, or charter, from investing in penny stock, or OTC companies. 

In the past, we have faced significantly high costs for capital raised.  We have been prevented from using more efficient and cost effective financing tools, which are available to firms listed on the national exchanges.  Unlike many companies who flounder on the OTC, Kraig Labs has managed to survive by being judicious in how we have raised capital, a process that has forced us to limit growth and which has slowed our progress toward commercialization.

The shareholders of Kraig Labs have also faced challenges relating to our penny stock and OTC status. Many brokerage firms will not accept penny stocks and are prohibited from informing their clients about penny stock opportunities.

It is with this experience that we now believe the time has come to consider the possibility of raising the Company to a national exchange and freeing ourselves of the burden of being a penny stock.  This move would provide access to institutional investment not currently available. Moving to a national exchange would lower the cost in raising the capital necessary to finance our growth.  The move would also be designed to provide greater liquidity for our shareholders.  The Board of Directors and management of Kraig Labs are committed to seeing our Company grow and we believe that the best path for this growth is to strengthen and reinforce our position as a publicly traded and publicly owned company by transitioning to a national exchange.

When the Company operated primarily as a small R&D operation, the burdens of being an OTC company were manageable, but, as we now move to commercialize our products and realize the potential of our technology, the time has come to start the next chapter by listing on a national exchange, a move that we believe will benefit the Company, all of our valued shareholders, and the global textile market.

The Company’s work to expand our corporate board, improve our financials, and strengthen corporate governance, including this shareholder meeting, have been a structured and methodical plan to meet the listing requirements for a national exchange, which include share price requirements.  During the upcoming annual meeting we are bringing this vision to all of you, the Company’s stakeholders, to vote on this strategy to unlock the potential of our Company and power of our technology.  We believe these moves will be a great benefit to our shareholders and our ability to capture a share of the global textile market.

After many years of measured and prudent moves, now is the right time for Kraig Labs to accelerate the next steps of our business model roll out and start the next chapter together.

Your voice and your vote are important; we encourage everyone to review all of the materials in the shareholder notice and to submit your proxy voting cards ahead of the annual meeting.  Our recent growth, over the last 12 months, has created a possible opportunity to uplist.  Let us move together and seize that opportunity.  

Thank you for your ongoing support, and good luck to all of us as we move boldly into the future.

Kim Thompson

CEO

Kraig Biocraft Laboratories, Inc.